Clinical Trial Update: AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AGEN1884 plus AGEN2034 with cisplatin-gemcitabine for muscle-invasive bladder cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urinary Bladder Neoplasms

Drugs mentioned

• AGEN1884 (anti-CTLA-4 monoclonal antibody)
• AGEN2034

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Urinary Bladder Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2024-04-04